Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

RCKT

Rocket Pharmaceuticals Inc

May 03 • 04:00PM ET

23.47

Dollar change +0.70
Percentage change 3.07	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF VB IBB VBK IWO SCHA VTWO LABU

Index	RUT	P/E	-	EPS (ttm)	-2.94	Insider Own	7.21%	Shs Outstand	90.28M	Perf Week	6.78%
Market Cap	2.13B	Forward P/E	-	EPS next Y	-1.81	Insider Trans	-6.30%	Shs Float	84.21M	Perf Month	-6.04%
Income	-245.59M	PEG	-	EPS next Q	-0.67	Inst Own	96.30%	Short Float	13.07%	Perf Quarter	-17.79%
Sales	0.00M	P/S	-	EPS this Y	10.22%	Inst Trans	5.54%	Short Ratio	14.92	Perf Half Y	23.53%
Book/sh	5.46	P/B	4.30	EPS next Y	31.03%	ROA	-43.93%	Short Interest	11.00M	Perf Year	32.15%
Cash/sh	4.11	P/C	5.71	EPS next 5Y	41.70%	ROE	-50.01%	52W Range	14.89 - 32.53	Perf YTD	-21.69%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-9.09%	ROI	-47.70%	52W High	-27.84%	Beta	1.09
Dividend TTM	-	Quick Ratio	7.80	Sales past 5Y	0.00%	Gross Margin	-	52W Low	57.62%	ATR (14)	1.11
Dividend Ex-Date	-	Current Ratio	7.80	EPS Y/Y TTM	10.53%	Oper. Margin	0.00%	RSI (14)	46.12	Volatility	4.49% 4.35%
Employees	268	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.14	Target Price	49.33
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	30.17%	Payout	-	Rel Volume	0.85	Prev Close	22.77
Sales Surprise	-	EPS Surprise	17.79%	Sales Q/Q	-	Earnings	Feb 26 AMC	Avg Volume	737.79K	Price	23.47
SMA20	-0.29%	SMA50	-9.83%	SMA200	1.45%	Trades		Volume	630,424	Change	3.07%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-24	Initiated	Goldman	Neutral	$39
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$65
Feb-01-23	Initiated	Morgan Stanley	Overweight	$45
Nov-08-22	Initiated	Canaccord Genuity	Buy	$53
Nov-01-22	Initiated	BTIG Research	Buy	$35
Jul-08-22	Initiated	Raymond James	Outperform	$22
Oct-20-21	Resumed	Cowen	Outperform
Mar-02-21	Initiated	Stifel	Buy	$64
Feb-18-21	Initiated	Needham	Buy	$75
Dec-16-20	Initiated	UBS	Buy	$75
Dec-08-20	Downgrade	Oppenheimer	Outperform → Perform
Jul-02-20	Initiated	JP Morgan	Overweight
Jun-25-20	Resumed	BofA/Merrill	Buy	$34
Jun-01-20	Resumed	Oppenheimer	Outperform
Nov-06-19	Initiated	Chardan Capital Markets	Buy	$30
Sep-26-19	Initiated	Piper Jaffray	Overweight
Apr-23-19	Initiated	Robert W. Baird	Outperform
Mar-15-19	Initiated	BofA/Merrill	Buy	$27
Feb-05-19	Initiated	Oppenheimer	Outperform	$39
Sep-13-18	Initiated	Ladenburg Thalmann	Buy	$30

Show Previous Ratings

Apr-30-24 12:00PM	Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why (Zacks)
Apr-24-24 11:33AM	Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
07:39AM	Should You Hold Immunovant (IMVT)? (Insider Monkey)
Apr-03-24 11:32AM	EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia (Zacks)
Apr-02-24 06:00AM	Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia (Business Wire)
11:30AM	Loading…
Mar-27-24 11:30AM	Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report? (Zacks)
Mar-26-24 04:01PM	Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team (Business Wire)
Feb-27-24 12:20PM	Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4 (Zacks)
Feb-26-24 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress (Business Wire)
Feb-13-24 07:00AM	Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire)
Jan-22-24 03:39AM	Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey) +5.61%
Jan-04-24 11:55AM	Amazon and Nvidia Stock Have a Lot More Growth Ahead, This Manager Says (Barrons.com)
Jan-02-24 04:01PM	Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-23 07:00AM	Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors (Business Wire)
Nov-23-23 12:16PM	Billionaire Lee Ainslies Top 10 Stock Picks (Insider Monkey)
11:17AM	Loading…
Nov-15-23 11:17AM	Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates (Zacks)
Nov-09-23 09:55AM	Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High? (Zacks) -7.15%
Nov-06-23 04:15PM	Rocket Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) -5.00%
04:04PM	Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
Nov-05-23 07:30AM	With This Rally, Rocket Just Might Take Off (TheStreet.com)
Nov-02-23 06:26PM	Rocket Pharmaceuticals Stock Sees Improved Price Strength (Investor's Business Daily)
Oct-27-23 02:49PM	Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher (Investor's Business Daily)
Oct-20-23 03:18AM	Should You Hold Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
Oct-19-23 07:00AM	Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Business Wire)
Oct-02-23 07:00AM	Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire) -5.08%
Sep-26-23 04:01PM	Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference (Business Wire)
Sep-23-23 09:45AM	Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals (Motley Fool)
Sep-18-23 07:30AM	Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread Carefully (Motley Fool)
Sep-15-23 11:00AM	Here's Why Rocket Pharmaceuticals (RCKT) Rises 53.8% in a Week (Zacks)
Sep-14-23 10:12AM	Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates (Zacks) +13.28%
04:34PM	Loading…
Sep-13-23 04:34PM	These Stocks Moved the Most Today: American Airlines, Moderna, Ford, Citigroup, Apple, and More (Barrons.com) +38.85%
01:50PM	Stock Market Not Too Rattled By Inflation Data; Trucking Stock Gets A Bounce (Investor's Business Daily)
01:36PM	These Stocks Are Moving the Most Today: American Airlines, Moderna, Ford, Citigroup, Apple, and More (Barrons.com)
12:30PM	Stock Market Weighs In On Inflation Data; Vaccine Maker Leads The S&P 500 (Investor's Business Daily)
12:23PM	What's Going On With Gene Therapy-Focused Rocket Pharmaceuticals Stock Today? (Benzinga)
12:15PM	Rocket Pharmaceuticals, Moderna rise; American Airlines, Spirit Airlines fall, Wednesday, 9/13/2023 (AP Finance)
11:56AM	Why Shares of Rocket Pharmaceuticals Are Taking Off on Wednesday (Motley Fool)
10:54AM	Rocket Pharmaceuticals Stock Jumps Most Since 2020. New Gene Therapy Is Potential Value Driver. (Barrons.com)
07:24AM	5 Things to Know Before Markets Open (Investopedia)
12:01AM	Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire)
Sep-12-23 04:02PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
04:01PM	Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease (Business Wire)
Sep-06-23 04:05PM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-10-23 07:14AM	Rocket Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
07:00AM	Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
Jul-29-23 11:39AM	10 Oversold Biotech Stocks to Buy (Insider Monkey)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey) +6.25%
Jun-12-23 04:34PM	3 Small-Cap Stocks You Cant Ignore Now (InvestorPlace)
Jun-09-23 09:24AM	Rocket (RCKT) Heart Disease Drug Gets Fast Track & Orphan Drug Tag (Zacks)
Jun-08-23 07:00AM	Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (Business Wire)
May-31-23 07:00AM	Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease (Business Wire)
May-23-23 07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD) (Business Wire)
May-19-23 06:00AM	Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Business Wire)
May-18-23 06:12AM	Heres Why Rocket Pharmaceuticals (RCKT) Stock Suffered in Q1 (Insider Monkey)
May-17-23 04:26PM	Fed, labor market concerns showing 'some dents in the armor of the consumer': Strategist (Yahoo Finance Video)
May-09-23 07:00AM	Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (Business Wire)
May-04-23 04:21PM	Rocket Pharmaceuticals: Q1 Earnings Snapshot (AP Finance) +5.24%
04:01PM	Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
May-03-23 04:01PM	Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference (Business Wire)
Apr-11-23 04:01PM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Apr-04-23 04:01PM	Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage (Business Wire)
Mar-01-23 04:01PM	Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference (Business Wire) +5.41%
Feb-27-23 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results (Business Wire)
Feb-09-23 04:01PM	Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference (Business Wire)
Feb-07-23 07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease (Business Wire)
Feb-05-23 09:07AM	Even with Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stock down 7.7% this week, insiders who bought recently netted around US$70k (Simply Wall St.)
Jan-28-23 01:30PM	12 Cash-Rich Small Cap Stocks To Invest In (Insider Monkey)
Jan-23-23 10:15AM	Rocket Pharmaceuticals (RCKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
09:55AM	Wall Street Analysts Think Rocket Pharmaceuticals (RCKT) Could Surge 163.35%: Read This Before Placing a Bet (Zacks)
Jan-09-23 04:01PM	Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease (Business Wire)
Jan-06-23 09:55AM	Wall Street Analysts Believe Rocket Pharmaceuticals (RCKT) Could Rally 170.92%: Here's is How to Trade (Zacks)
Jan-03-23 04:01PM	Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-22-22 06:00AM	Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting (Business Wire) -13.90%
Dec-12-22 10:00AM	Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting (Business Wire) +6.58%
Dec-11-22 07:21PM	TipRanks Perfect 10 List: These 3 Top-Rated Stocks Could Shine in 2023 (TipRanks)
Dec-01-22 04:01PM	Rocket Pharmaceuticals Completes Acquisition of Renovacor (Business Wire)
Nov-21-22 08:00AM	Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-16-22 07:59AM	A Look At The Fair Value Of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (Simply Wall St.) -5.99%
Nov-03-22 04:01PM	Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress (Business Wire)
09:00AM	Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses (Business Wire)
Oct-27-22 09:55AM	Wall Street Analysts See an 184% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High? (Zacks)
Oct-14-22 06:35PM	Alkermes, Allakos, and Other Stocks See Action From Activist Investors (Barrons.com)
Oct-12-22 06:00AM	Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Business Wire)
Oct-11-22 09:55AM	Does Rocket Pharmaceuticals (RCKT) Have the Potential to Rally 212% as Wall Street Analysts Expect? (Zacks)
Oct-10-22 08:00AM	Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa (Business Wire)
Oct-03-22 11:21PM	Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire)
04:42PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Sep-30-22 06:00AM	Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 (Business Wire) +13.68%
Sep-27-22 08:00AM	Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference (Business Wire) +7.41%
Sep-20-22 05:07PM	Cambridge biotech acquired for $53M following move from Philadelphia (American City Business Journals)
11:14AM	Why Is Renovacor (RCOR) Stock Up 18% Today? (InvestorPlace)
10:06AM	Rocket Pharmaceuticals Buys Renovacor, Strengthening Position In Gene Therapies For Heart Diseases (Benzinga)
06:00AM	Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy (Business Wire)
Sep-16-22 08:00AM	Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 (Business Wire) -10.21%
Sep-06-22 08:00AM	Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference (Business Wire) -5.66%
Aug-15-22 09:13AM	15 Small Company Stocks You Should Own Now for the Next Decade (Insider Monkey)
Aug-11-22 02:11PM	Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade (Investor's Business Daily)
Aug-08-22 04:01PM	Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress (Business Wire)
Jul-27-22 07:00AM	Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities (Business Wire)
Jul-20-22 06:33AM	A Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) insider increased their holdings by 2.4% last year (Simply Wall St.)

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Militello John	See Remarks	Apr 22 '24	Sale	22.87	833	19,051	54,406	Apr 24 04:06 PM
SOUTHWELL DAVID P	Director	Apr 15 '24	Option Exercise	4.34	29,624	128,627	124,784	Apr 16 05:45 PM
SOUTHWELL DAVID P	Director	Apr 15 '24	Sale	24.05	10,000	240,520	114,784	Apr 16 05:45 PM
SOUTHWELL DAVID P	Director	Apr 12 '24	Option Exercise	4.34	70,000	303,940	165,160	Apr 16 05:45 PM
SOUTHWELL DAVID P	Director	Apr 12 '24	Sale	24.36	70,000	1,705,265	95,160	Apr 16 05:45 PM
White Mark Andrew	See Remarks	Apr 08 '24	Sale	24.64	12,532	308,763	75,226	Apr 10 08:39 PM
Makker Gotham	Director	Mar 21 '24	Sale	28.43	274,000	7,790,943	365,912	Mar 25 08:58 PM
Militello John	See Remarks	Mar 21 '24	Sale	28.10	2,490	69,979	55,239	Mar 25 08:54 PM
Militello John	See Remarks	Feb 29 '24	Option Exercise	12.55	10,000	125,500	31,517	Mar 04 06:54 PM
Militello John	See Remarks	Feb 29 '24	Sale	29.84	10,000	298,450	21,517	Mar 04 06:54 PM
Wilson Martin	General Counsel	Feb 29 '24	Sale	29.33	4,100	120,257	18,680	Mar 04 06:48 PM
Shah Gaurav	CEO	Feb 16 '24	Sale	29.84	20,272	604,876	554,762	Feb 21 08:54 PM
Patel Kinnari	See Remarks	Feb 16 '24	Sale	29.84	7,132	212,805	238,346	Feb 21 08:54 PM
Wilson Martin	General Counsel	Feb 16 '24	Sale	29.84	3,576	106,701	6,136	Feb 21 08:54 PM
Militello John	See Remarks	Feb 16 '24	Sale	29.84	3,238	96,615	13,195	Feb 21 08:54 PM
Militello John	See Remarks	Feb 14 '24	Option Exercise	0.00	6,274	0	16,433	Feb 16 04:05 PM
Patel Kinnari	See Remarks	Feb 14 '24	Option Exercise	0.00	26,189	0	245,478	Feb 16 04:05 PM
Militello John	See Remarks	Jan 22 '24	Sale	27.20	638	17,356	10,159	Jan 23 04:22 PM
Militello John	See Remarks	Jan 18 '24	Option Exercise	0.00	1,586	0	10,797	Jan 22 04:05 PM
Makker Gotham	Director	Nov 15 '23	Sale	22.53	20,000	450,646	1,296,497	Nov 16 07:24 PM
Militello John	See Remarks	Nov 14 '23	Option Exercise	0.00	725	0	9,485	Nov 16 06:58 PM
Patel Kinnari	See Remarks	Nov 14 '23	Option Exercise	0.00	3,989	0	220,437	Nov 16 07:17 PM
Militello John	See Remarks	Oct 20 '23	Sale	17.06	564	9,623	8,760	Oct 25 09:38 AM
Patel Kinnari	See Remarks	Oct 05 '23	Option Exercise	0.00	3,333	0	101,594	Oct 10 04:11 PM
Makker Gotham	Director	Sep 29 '23	Sale	21.14	4,677	98,864	1,316,497	Oct 02 09:02 PM
Makker Gotham	Director	Sep 28 '23	Sale	21.03	10,312	216,880	1,321,174	Oct 02 09:02 PM
Shah Gaurav	CEO	Aug 17 '23	Sale	15.47	4,767	73,750	524,854	Aug 21 04:05 PM
Patel Kinnari	See Remarks	Aug 17 '23	Sale	15.47	1,534	23,733	216,448	Aug 21 04:05 PM
Militello John	See Remarks	Aug 17 '23	Sale	15.47	284	4,394	5,570	Aug 21 04:05 PM
Patel Kinnari	See Remarks	Aug 14 '23	Option Exercise	0.00	3,989	0	217,982	Aug 15 04:16 PM
Militello John	See Remarks	Aug 14 '23	Option Exercise	0.00	725	0	7,854	Aug 15 04:17 PM
Shah Gaurav	CEO	Aug 14 '23	Option Exercise	0.00	7,979	0	529,621	Aug 15 04:06 PM
Militello John	See Remarks	Jul 20 '23	Sale	19.03	573	10,906	7,129	Jul 24 04:05 PM
Militello John	See Remarks	Jul 18 '23	Option Exercise	0.00	1,586	0	7,702	Jul 20 04:05 PM
Shah Gaurav	CEO	May 17 '23	Sale	21.38	4,122	88,108	521,642	May 19 04:05 PM
Patel Kinnari	See Remarks	May 17 '23	Sale	21.38	1,330	28,429	213,993	May 19 04:05 PM
Militello John	See Remarks	May 17 '23	Sale	21.38	245	5,237	6,116	May 19 04:05 PM
Militello John	See Remarks	May 14 '23	Option Exercise	0.00	725	0	6,361	May 16 08:01 PM
Shah Gaurav	CEO	May 14 '23	Option Exercise	0.00	7,979	0	525,764	May 16 08:04 PM
Patel Kinnari	See Remarks	May 14 '23	Option Exercise	0.00	3,989	0	215,323	May 16 07:57 PM

Open in Screener

PTCT

PTC Therapeutics Inc

May 03 • 04:00PM ET

33.01

Dollar change -0.61
Percentage change -1.81	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

PTCT PTC Therapeutics Inc daily Stock Chart

Held by: VTI IWM VB VXF VBK IBB IWO SCHA PBE VTWO

Index	RUT	P/E	-	EPS (ttm)	-7.69	Insider Own	3.78%	Shs Outstand	75.71M	Perf Week	15.54%
Market Cap	2.53B	Forward P/E	-	EPS next Y	-4.52	Insider Trans	-1.51%	Shs Float	73.80M	Perf Month	18.66%
Income	-579.22M	PEG	-	EPS next Q	-1.26	Inst Own	109.98%	Short Float	13.83%	Perf Quarter	31.10%
Sales	927.56M	P/S	2.73	EPS this Y	31.22%	Inst Trans	1.91%	Short Ratio	11.20	Perf Half Y	78.92%
Book/sh	-11.66	P/B	-	EPS next Y	21.45%	ROA	-34.09%	Short Interest	10.20M	Perf Year	-40.43%
Cash/sh	11.54	P/C	2.86	EPS next 5Y	-9.51%	ROE	-	52W Range	17.53 - 59.84	Perf YTD	19.78%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-24.94%	ROI	-	52W High	-44.84%	Beta	0.68
Dividend TTM	-	Quick Ratio	1.98	Sales past 5Y	29.08%	Gross Margin	67.57%	52W Low	88.31%	ATR (14)	1.82
Dividend Ex-Date	-	Current Ratio	2.03	EPS Y/Y TTM	2.63%	Oper. Margin	-30.16%	RSI (14)	67.42	Volatility	7.80% 5.92%
Employees	995	Debt/Eq	-	Sales Y/Y TTM	20.39%	Profit Margin	-62.45%	Recom	2.79	Target Price	29.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	36.48%	Payout	-	Rel Volume	1.09	Prev Close	33.62
Sales Surprise	26.97%	EPS Surprise	5.86%	Sales Q/Q	-4.66%	Earnings	Apr 25 AMC	Avg Volume	911.22K	Price	33.01
SMA20	19.80%	SMA50	15.19%	SMA200	15.56%	Trades		Volume	992,557	Change	-1.81%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$28
Dec-08-23	Initiated	Wells Fargo	Overweight	$37
Oct-30-23	Upgrade	Oppenheimer	Perform → Outperform	$165
Oct-27-23	Downgrade	Citigroup	Neutral → Sell	$29 → $17
Oct-06-23	Downgrade	Truist	Buy → Hold	$45 → $25
Sep-18-23	Downgrade	Citigroup	Buy → Neutral	$55 → $28
Sep-15-23	Downgrade	Raymond James	Outperform → Underperform
Mar-17-23	Initiated	SVB Securities	Market Perform	$48
Dec-14-22	Initiated	Goldman	Sell	$35
Sep-12-22	Initiated	Jefferies	Buy	$62
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$54
Sep-01-22	Initiated	Citigroup	Buy	$70
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight	$64 → $63
Oct-18-21	Downgrade	BofA Securities	Neutral → Underperform	$38
Apr-26-21	Resumed	Credit Suisse	Neutral	$54
Mar-29-21	Upgrade	RBC Capital Mkts	Underperform → Sector Perform	$47
Feb-12-21	Downgrade	BofA Securities	Buy → Neutral
Jan-05-21	Upgrade	Citigroup	Neutral → Buy	$67 → $85
Nov-30-20	Downgrade	RBC Capital Mkts	Sector Perform → Underperform	$45
Oct-30-20	Downgrade	Citigroup	Buy → Neutral

Show Previous Ratings

May-02-24 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
May-01-24 02:45PM	PTC Therapeutics Stock Sees IBD RS Rating Climb To 72 (Investor's Business Daily) +6.25%
Apr-30-24 12:25PM	PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-29-24 06:11AM	Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28 (MT Newswires) +12.50%
Apr-26-24 03:57PM	Sector Update: Health Care Stocks Edge Higher Late Afternoon (MT Newswires) +12.08%
11:16AM	Loading…
11:16AM	PTC Therapeutics Shares Rise After Better-Than-Expected Q1 Results (MT Newswires)
07:11AM	Q1 2024 PTC Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:35AM	PTC Therapeutics Inc (PTCT) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ... (GuruFocus.com)
Apr-25-24 08:56PM	PTCT Stock Earnings: PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00PM	Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics (Zacks)
05:39PM	PTC Therapeutics Q1 2024 Earnings: A Detailed Financial Review (GuruFocus.com)
04:53PM	PTC Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-23-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-18-24 10:01AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	Loading…
Apr-11-24 08:00AM	PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results (PR Newswire)
Mar-28-24 08:30AM	PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA (PR Newswire)
Mar-25-24 10:00AM	A Comprehensive Look at Sarepta's Growth and Innovation (GuruFocus.com)
Mar-20-24 02:00PM	PTC Therapeutics (PTCT) Up on Positive Regulatory Updates (Zacks)
Mar-19-24 07:30AM	PTC Therapeutics Provides Key Regulatory Updates (PR Newswire)
Mar-02-24 08:56AM	PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 06:51AM	Q4 2023 PTC Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +13.34%
Feb-29-24 06:00PM	Here's What Key Metrics Tell Us About PTC Therapeutics (PTCT) Q4 Earnings (Zacks)
05:20PM	PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:33PM	PTC Therapeutics Inc (PTCT) Reports Robust Revenue Growth and Advances in Pipeline (GuruFocus.com)
04:30PM	PTC Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Feb-27-24 05:20PM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Feb-26-24 09:16AM	Wall Street's Insights Into Key Metrics Ahead of PTC Therapeutics (PTCT) Q4 Earnings (Zacks)
Feb-22-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
08:00AM	Loading…
Feb-15-24 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Feb-13-24 10:00AM	PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks) -6.83%
Feb-11-24 01:45AM	1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock? (Motley Fool)
Jan-26-24 04:06PM	PTC Therapeutics Recovers From An Ugly Fall After European Officials Reject DMD Drug (Investor's Business Daily)
11:45AM	PTC Therapeutics Recovers, Mostly, After European Officials Reject DMD Drug (Investor's Business Daily)
10:18AM	PTC Therapeutics Flashes A Bearish Sign After European Officials Reject DMD Drug (Investor's Business Daily)
Jan-25-24 04:51PM	UPDATE 1-Europe to withdraw PTC Therapeutics' rare muscle disorder drug (Reuters)
04:20PM	PTC Therapeutics' muscle disorder drug fails to secure EU regulator backing (Reuters)
04:05PM	CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna (ataluren) Following Re-examination Procedure (PR Newswire)
Jan-24-24 07:02PM	PTC Therapeutics Inc Director Allan Jacobson Sells 10,000 Shares (GuruFocus.com)
Jan-12-24 01:02AM	PTC Therapeutics Inc Chief Business Officer Eric Pauwels Sells 3,634 Shares (GuruFocus.com) -5.01%
Jan-08-24 09:26AM	PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) +7.49%
Jan-03-24 08:00AM	PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-20-23 09:41AM	Analysts on Wall Street Lower Ratings for These 5 Stocks (Insider Monkey)
Dec-15-23 05:01PM	Insider Buying: CFO Pierre Gravier Acquires 7,700 Shares of PTC Therapeutics Inc (PTCT) (GuruFocus.com)
Dec-14-23 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-05-23 04:15PM	PTC Therapeutics Provides Updates on Translarna Regulatory Activities (PR Newswire)
Nov-14-23 03:58PM	FMR LLC Trims Stake in PTC Therapeutics Inc (GuruFocus.com) +9.71%
Nov-03-23 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +8.08%
Oct-30-23 09:03AM	PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-27-23 11:22AM	Q3 2023 PTC Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -22.71%
10:01AM	Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls (The Fly)
08:33AM	Why Is PTC Therapeutics (PTCT) Stock Down 23% Today? (InvestorPlace)
07:15AM	The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical (Zacks)
02:38AM	Southwest Airlines slashed at TD Cowen following Q3 miss: 4 big analyst cuts (Investing.com)
Oct-26-23 07:30PM	PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:10PM	PTC Therapeutics Inc (PTCT) Reports Q3 2023 Earnings: Revenue of $197 Million (GuruFocus.com)
05:30PM	PTC Therapeutics (PTCT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:25PM	PTC Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results (PR Newswire)
Oct-24-23 10:00AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-19-23 07:02PM	Why PTC Therapeutics Soared 15% Higher Today (Motley Fool) +14.98%
10:01AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	PTC Therapeutics Announces Evrysdi Royalty Agreement with Royalty Pharma for Up To $1.5 Billion (PR Newswire)
Oct-16-23 04:30PM	PTC Therapeutics to Host Conference Call to DiscussThird Quarter 2023 Financial Results (PR Newswire)
Oct-11-23 08:07AM	PTC Therapeutics (PTCT) Moves 5.3% Higher: Will This Strength Last? (Zacks)
Oct-06-23 09:42AM	e.l.f. Beauty upgraded, AutoZone downgraded: Wall Street's top analyst calls (The Fly)
Sep-29-23 11:18AM	PTC Therapeutics (PTCT) to Cut 25% Jobs by January 2024 (Zacks)
Sep-28-23 05:15PM	UPDATE 2-PTC Therapeutics announces job cuts to lower annual operating expenses (Reuters)
04:42PM	PTC Therapeutics announces job cuts (Reuters)
04:30PM	PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce (PR Newswire)
Sep-25-23 03:18AM	PTC Therapeutics (PTCT) Lost 16% in Q2 (Insider Monkey) -5.69%
Sep-20-23 04:00AM	PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains? (Zacks)
Sep-19-23 06:46AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey) +5.77%
Sep-15-23 04:04PM	Biotech Crashes 30% After European Regulators Yank Approval For Muscle Disease Drug (Investor's Business Daily) -29.77%
09:28AM	PTC Therapeutics Crashes 29% After European Regulators Reject Its Muscular Dystrophy Drug (Investor's Business Daily)
06:00AM	CHMP Delivers Opinion on Translarna for Conversion to Full Authorization (PR Newswire)
Sep-12-23 08:00AM	Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors (GlobeNewswire)
Sep-07-23 07:33PM	Is PTC Therapeutics (PTCT) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com)
08:00AM	PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community (PR Newswire)
08:00AM	Australian Patient Advocacy Organization Named a Recipient of PTC Therapeutics' 2023 STRIVE Award for Duchenne Muscular Dystrophy (PR Newswire)
Aug-30-23 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-28-23 08:00AM	PTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium (PR Newswire)
Aug-25-23 01:38PM	Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases (InvestorPlace)
Aug-04-23 01:24PM	PTC Therapeutics, Inc. (NASDAQ:PTCT) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 09:30PM	PTC Therapeutics (PTCT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:25PM	PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:14PM	PTC Therapeutics: Q2 Earnings Snapshot (AP Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results (PR Newswire)
Jul-21-23 09:30AM	CHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy (PR Newswire)
Jul-20-23 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results (PR Newswire)
Jul-19-23 04:30PM	PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize (PR Newswire)
Jul-18-23 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-17-23 04:30PM	PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer (PR Newswire)
Jul-11-23 12:00PM	PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin (PR Newswire)
Jun-30-23 10:18AM	PTC Therapeutics' Seizure Study Fails To Meet Primary Goal, Analyst Says Minimal Impact On Investment Thesis (Benzinga)
Jun-29-23 04:30PM	PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures (PR Newswire)
09:18AM	Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7% (Zacks)
Jun-28-23 07:41AM	PTC Therapeutics' (NASDAQ:PTCT) investors will be pleased with their 21% return over the last five years (Simply Wall St.)
Jun-21-23 04:24PM	PTC Therapeutics Says Interim Data For Huntington's Disease Candidate Shows Promise In Mid-Stage Study (Benzinga)

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Apr 19 '24	Sale	24.89	3,361	83,669	225,807	Apr 22 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Apr 17 '24	Sale	25.14	1,307	32,851	229,168	Apr 19 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Apr 17 '24	Sale	25.14	787	19,781	67,694	Apr 19 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Apr 02 '24	Sale	28.37	526	14,923	59,988	Apr 04 05:16 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 30 '24	Sale	27.25	794	21,637	71,189	Feb 01 04:17 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 30 '24	Sale	27.25	618	16,841	61,202	Feb 01 04:18 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 30 '24	Sale	27.25	366	9,974	44,181	Feb 01 04:16 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 30 '24	Sale	27.25	318	8,666	35,528	Feb 01 04:15 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 30 '24	Sale	27.25	28	763	3,706	Feb 01 04:18 PM
Jacobson Allan Steven	Director	Jan 22 '24	Option Exercise	27.05	10,000	270,500	22,348	Jan 24 04:30 PM
Jacobson Allan Steven	Director	Jan 22 '24	Sale	27.38	10,000	273,804	12,348	Jan 24 04:30 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 09 '24	Sale	29.01	5,443	157,928	160,475	Jan 10 04:08 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 09 '24	Sale	29.01	2,065	59,916	44,547	Jan 10 04:09 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 09 '24	Sale	29.01	1,938	56,231	71,983	Jan 10 04:04 PM
Utter Christine Marie	SVP, FINANCE & CAO	Jan 09 '24	Sale	29.01	1,653	47,961	35,846	Jan 10 04:11 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 09 '24	Sale	29.01	1,521	44,132	61,820	Jan 10 04:03 PM
Golden Lee Scott	CHIEF MEDICAL OFFICER	Jan 09 '24	Sale	29.01	1,225	35,543	37,914	Jan 10 04:06 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 09 '24	Sale	29.01	100	2,901	3,734	Jan 10 04:03 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 08 '24	Sale	28.64	2,237	64,068	165,918	Jan 10 04:08 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 08 '24	Sale	28.64	1,569	44,937	46,612	Jan 10 04:09 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 08 '24	Sale	28.64	1,457	41,729	73,921	Jan 10 04:04 PM
SCHMERTZLER MICHAEL	Director	Jan 08 '24	Sale	27.81	1,500	41,715	115,266	Jan 10 04:10 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '24	Sale	28.64	1,236	35,399	63,341	Jan 10 04:03 PM
Utter Christine Marie	SVP, FINANCE & CAO	Jan 08 '24	Sale	28.64	1,188	34,025	37,499	Jan 10 04:11 PM
Golden Lee Scott	CHIEF MEDICAL OFFICER	Jan 08 '24	Sale	28.64	775	22,196	39,139	Jan 10 04:06 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '24	Sale	28.64	53	1,518	3,834	Jan 10 04:03 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 05 '24	Sale	27.15	10,107	274,393	168,155	Jan 09 04:29 PM
Gravier Pierre	CHIEF FINANCIAL OFFICER	Dec 12 '23	Buy	25.81	7,700	198,736	33,700	Dec 14 04:38 PM
Young Alethia	Director	Sep 06 '23	Option Exercise	27.85	11,666	324,898	16,067	Sep 08 04:02 PM
Young Alethia	Director	Sep 06 '23	Sale	39.86	11,666	464,972	9,067	Sep 08 04:02 PM
SCHMERTZLER MICHAEL	Director	Jun 07 '23	Sale	44.86	1,000	44,860	116,766	Jun 09 04:03 PM
Reeve Emma	Director	May 23 '23	Option Exercise	33.38	2,652	88,520	8,602	May 24 04:12 PM
Reeve Emma	Director	May 23 '23	Sale	59.53	2,652	157,885	7,200	May 24 04:12 PM
Reeve Emma	Director	May 22 '23	Option Exercise	33.37	7,116	237,484	11,148	May 24 04:12 PM
Reeve Emma	Director	May 22 '23	Sale	59.53	7,116	423,630	7,200	May 24 04:12 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	May 22 '23	Sale	59.01	2,013	118,791	47,553	May 23 04:05 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	May 19 '23	Sale	58.96	6,403	377,491	49,566	May 23 04:05 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	May 18 '23	Sale	58.71	788	46,267	55,969	May 19 04:04 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	May 17 '23	Sale	58.50	8,048	470,822	56,757	May 19 04:04 PM
Jacobson Allan Steven	Director	May 11 '23	Option Exercise	10.85	23,000	249,550	35,348	May 12 04:08 PM
Jacobson Allan Steven	Director	May 11 '23	Sale	55.08	23,000	1,266,930	12,348	May 12 04:08 PM

Open in Screener

TCRX

Tscan Therapeutics Inc

May 03 • 04:00PM ET

8.56

Dollar change -0.09
Percentage change -1.04	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

TCRX Tscan Therapeutics Inc daily Stock Chart

Held by: VTI SURI VXF DWAS IWC AVSC BMED DFUS DFAU

Index	-	P/E	-	EPS (ttm)	-1.89	Insider Own	16.42%	Shs Outstand	47.83M	Perf Week	16.94%
Market Cap	394.62M	Forward P/E	-	EPS next Y	-1.14	Insider Trans	0.45%	Shs Float	38.53M	Perf Month	20.73%
Income	-89.22M	PEG	-	EPS next Q	-0.26	Inst Own	58.32%	Short Float	1.09%	Perf Quarter	63.36%
Sales	21.05M	P/S	18.75	EPS this Y	23.24%	Inst Trans	-0.36%	Short Ratio	1.99	Perf Half Y	136.46%
Book/sh	3.15	P/B	2.71	EPS next Y	-9.43%	ROA	-37.87%	Short Interest	0.42M	Perf Year	273.80%
Cash/sh	4.17	P/C	2.05	EPS next 5Y	-	ROE	-71.29%	52W Range	1.93 - 9.00	Perf YTD	46.83%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-25.53%	ROI	-37.69%	52W High	-4.89%	Beta	0.91
Dividend TTM	-	Quick Ratio	6.51	Sales past 5Y	230.91%	Gross Margin	74.53%	52W Low	343.52%	ATR (14)	0.52
Dividend Ex-Date	-	Current Ratio	6.51	EPS Y/Y TTM	31.37%	Oper. Margin	-444.00%	RSI (14)	67.39	Volatility	6.83% 6.66%
Employees	154	Debt/Eq	0.61	Sales Y/Y TTM	55.52%	Profit Margin	-423.86%	Recom	1.20	Target Price	11.00
Option/Short	No / Yes	LT Debt/Eq	0.57	EPS Q/Q	73.41%	Payout	-	Rel Volume	0.42	Prev Close	8.65
Sales Surprise	108.77%	EPS Surprise	27.39%	Sales Q/Q	132.99%	Earnings	Mar 06 BMO	Avg Volume	211.00K	Price	8.56
SMA20	14.89%	SMA50	17.95%	SMA200	75.94%	Trades		Volume	88,679	Change	-1.04%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-22-23	Initiated	Wedbush	Outperform	$8

May-01-24 10:01AM	TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +11.66%
Apr-24-24 04:05PM	TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
11:03AM	TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Apr-22-24 05:01PM	TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting (GlobeNewswire)
Apr-19-24 10:05AM	TScan Therapeutics Announces Closing of Upsized Public Offering (GlobeNewswire)
12:30AM	Loading…
Apr-17-24 12:30AM	TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering (GlobeNewswire) -5.33%
Apr-16-24 04:25PM	TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering (GlobeNewswire) -7.28%
04:01PM	TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities (GlobeNewswire)
Apr-08-24 08:00AM	TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer (GlobeNewswire)
Apr-02-24 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -10.11%
Mar-17-24 02:58PM	Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With (InvestorPlace)
Mar-07-24 01:44PM	TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline (GuruFocus.com)
Mar-06-24 01:51PM	TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Loading…
Feb-28-24 07:00AM	TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-26-24 07:00AM	TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-19-24 05:49AM	TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar? (Zacks)
Feb-14-24 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-06-24 07:00AM	TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development (GlobeNewswire) +6.67%
Jan-29-24 07:00AM	TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer (GlobeNewswire)
Jan-18-24 07:00AM	TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire) -9.62%
Jan-04-24 07:00AM	TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress (GlobeNewswire)
Dec-09-23 12:00PM	TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Dec-07-23 07:00AM	TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations (GlobeNewswire)
Dec-06-23 08:50AM	Recent Price Trend in TScan Therapeutics, Inc. (TCRX) is Your Friend, Here's Why (Zacks)
Dec-04-23 04:05PM	TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition (GlobeNewswire) -5.56%
07:00AM	TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer (GlobeNewswire)
Dec-01-23 09:55AM	Does TScan Therapeutics, Inc. (TCRX) Have the Potential to Rally 62.33% as Wall Street Analysts Expect? (Zacks)
Nov-30-23 07:00AM	TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years (GlobeNewswire) +12.98%
12:00PM	Loading…
Nov-27-23 12:00PM	TScan Therapeutics, Inc. (TCRX) is a Great Momentum Stock: Should You Buy? (Zacks)
Nov-20-23 08:50AM	TScan Therapeutics, Inc. (TCRX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) -13.83%
Nov-15-23 12:00PM	What Makes TScan Therapeutics, Inc. (TCRX) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Predict a 125% Upside in TScan Therapeutics, Inc. (TCRX): Here's What You Should Know (Zacks)
Nov-09-23 08:25AM	TScan Therapeutics Inc (TCRX) Reports Q3 2023 Financial Results and Corporate Updates (GuruFocus.com)
07:00AM	TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-23 07:00AM	TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting (GlobeNewswire) +11.03%
Nov-02-23 09:05AM	TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) +7.73%
Oct-12-23 12:00PM	TScan Therapeutics, Inc. (TCRX) Upgraded to Strong Buy: Here's Why (Zacks)
Sep-27-23 09:06AM	TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-12-23 08:00AM	Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors (GlobeNewswire)
Sep-05-23 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-29-23 07:00AM	TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME (GlobeNewswire) +10.96%
Aug-16-23 12:00PM	TScan Therapeutics, Inc. (TCRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-10-23 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-13-23 07:25AM	Shareholders in TScan Therapeutics (NASDAQ:TCRX) are in the red if they invested a year ago (Simply Wall St.)
Jun-29-23 07:00AM	TScan Therapeutics Announces Transition of Chief Financial Officer (GlobeNewswire)
Jun-15-23 07:42AM	Favourable Signals For TScan Therapeutics: Numerous Insiders Acquired Stock \ (Simply Wall St.)
Jun-06-23 07:00AM	TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors (GlobeNewswire)
Jun-01-23 04:10PM	TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
04:05PM	TScan Therapeutics Announces Closing of Public Offering (GlobeNewswire)
07:00AM	TScan Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-26-23 12:37AM	TScan Therapeutics Announces Pricing of $140 Million Public Offering (GlobeNewswire) +31.28%
May-25-23 04:06PM	TScan Therapeutics Announces Launch of Proposed Public Offering (GlobeNewswire)
May-24-23 04:13PM	TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors (GlobeNewswire)
May-17-23 04:35PM	TScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia Patients (Benzinga) -10.53%
07:00AM	TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting (GlobeNewswire)
May-11-23 07:33AM	Institutional investors control 30% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 112% (Simply Wall St.) -7.22%
May-10-23 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +42.65%
07:00AM	TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 01:29PM	Why Are TScan Therapeutics Shares Are Shooting Higher Today (Benzinga) +51.14%
09:00AM	Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohns Disease (GlobeNewswire)
May-02-23 04:42PM	TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire) +26.22%
Apr-10-23 07:00AM	TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors (GlobeNewswire)
Mar-31-23 08:00AM	TScan Therapeutics Announces CEO Transition (GlobeNewswire) -18.29%
Mar-14-23 07:00AM	TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies (GlobeNewswire)
Mar-13-23 04:05PM	TScan Therapeutics to Participate in the Barclays Global Healthcare Conference (GlobeNewswire) -13.31%
Mar-10-23 05:12AM	TScan Therapeutics Full Year 2022 Earnings: Misses Expectations (Simply Wall St.)
Mar-08-23 07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones (GlobeNewswire)
Mar-01-23 07:00AM	TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire) +6.78%
Feb-21-23 07:00AM	TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Jan-23-23 07:00AM	TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors (GlobeNewswire)
Jan-20-23 05:35AM	Shareholders in TScan Therapeutics (NASDAQ:TCRX) are in the red if they invested a year ago (Simply Wall St.)
Jan-05-23 07:00AM	TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress (GlobeNewswire)
Dec-12-22 07:00AM	TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022 (GlobeNewswire)
Dec-09-22 06:09AM	A number of insiders bought TScan Therapeutics, Inc. (NASDAQ:TCRX) stock last year, which is great news for shareholders (Simply Wall St.)
Dec-01-22 08:00AM	TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe (GlobeNewswire)
Nov-22-22 07:00AM	TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-11-22 07:00AM	TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) +7.81%
Nov-09-22 07:00AM	TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 07:00AM	TScan Therapeutics Announces Upcoming Virtual Investor Event (GlobeNewswire)
Nov-03-22 09:34AM	TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) +8.65%
Oct-05-22 08:33AM	TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-28-22 09:21AM	Chinese Billionaire Zhang Lei is Selling These 10 Stocks (Insider Monkey)
Sep-22-22 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -8.28%
Sep-12-22 07:00AM	TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures (GlobeNewswire)
Sep-07-22 07:00AM	TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire) +12.12%
Aug-13-22 08:14AM	TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates (Simply Wall St.)
Aug-12-22 06:08AM	New Forecasts: Here's What Analysts Think The Future Holds For TScan Therapeutics, Inc. (NASDAQ:TCRX) (Simply Wall St.) -5.41%
Aug-10-22 07:00AM	TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress (GlobeNewswire) -9.88%
Aug-05-22 11:58AM	Shareholders in TScan Therapeutics (NASDAQ:TCRX) are in the red if they invested a year ago (Simply Wall St.)
Aug-03-22 07:00AM	TScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-11-22 07:00AM	TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology (GlobeNewswire)
Jul-07-22 07:00AM	TScan Therapeutics Appoints Debora Barton, M.D., as Chief Medical Officer (GlobeNewswire)
Jul-06-22 08:28AM	Is TScan Therapeutics (NASDAQ:TCRX) In A Good Position To Invest In Growth? (Simply Wall St.)
Jun-22-22 07:00AM	TScan Therapeutics to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium (GlobeNewswire) +5.28%
Jun-02-22 07:00AM	TScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-31-22 07:00AM	TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies (GlobeNewswire)
May-22-22 08:03AM	Insider Buying: The TScan Therapeutics, Inc. (NASDAQ:TCRX) President Just Bought 17% More Shares (Simply Wall St.)

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BARBERICH TIMOTHY J	Director	Dec 19 '23	Buy	4.97	317	1,575	67,027	Dec 21 05:00 PM
BARBERICH TIMOTHY J	Director	Dec 18 '23	Buy	4.89	28,830	140,881	66,710	Dec 21 05:00 PM
Klencke Barbara	Director	Dec 14 '23	Buy	5.08	5,000	25,400	30,000	Dec 18 06:01 PM
BARBERICH TIMOTHY J	Director	Jun 02 '23	Buy	2.63	37,880	99,564	37,880	Jun 06 07:53 PM
Lynx1 Capital Management LP	10% Owner	May 31 '23	Sale	2.52	25,400	63,952	5,224,600	Jun 02 05:35 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

RCKT

Rocket Pharmaceuticals Inc

PTCT

PTC Therapeutics Inc

TCRX

Tscan Therapeutics Inc

Upgrade your FINVIZ experience